Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 14;7(21):6762-6766.
doi: 10.1182/bloodadvances.2023010742.

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Alessandro Broccoli  1   2 , Lisa Argnani  2 , Laura Nanni  1   2 , Vittorio Stefoni  1   2 , Cinzia Pellegrini  1 , Beatrice Casadei  1 , Gabriele Gugliotta  1 , Matteo Carella  1   2 , Paolo Elia Coppola  1   2 , Gianmarco Bagnato  1   2 , Pier Luigi Zinzani  1   2
Affiliations

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Alessandro Broccoli et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Time to next treatment and survival analysis. (A) TTNT calculated on each treatment received (it includes also patients who received rituximab more than once). (B) Progression-free survival determined on 33 patients from the initiation of the (first) treatment with rituximab to the date of progression, death, or last follow-up. (C) Overall survival determined on 33 patients from the initiation of the (first) treatment with rituximab to the date of death or last follow-up.
See this image and copyright information in PMC

References

    1. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733–740. - PubMed
    1. Cornet E, Tomowiak C, Tanguy-Schmidt A, et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol. 2014;166(3):390–400. - PubMed
    1. Zinzani PL, Stefoni V, Broccoli A, et al. Is it really possible to cure hairy cell leukemia patients only with frontline therapy? Ann Hematol. 2014;93(9):1565–1569. - PubMed
    1. Broccoli A, Argnani L, Nanni L, et al. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a 30-year experience. Am J Hematol. 2021;96(10):1204–1210. - PubMed
    1. Broccoli A, Argnani L, Cross M, et al. A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. Blood Adv. 2022;6(14):4224–4227. - PMC - PubMed

Publication types